Skip to content

Comparison of the efficacy of 3 drug groups :Midazolam, Propofol , and Midazolam- Propofol in prevention of pruritis induced by anesthetic drug used for syrgery

Comparison of the efficacy of Midazolam, Propofol , and Midazolam-Propofol in prevention of pruritis induced by intrathecal Sufentanil in patients under surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201203059213N1
Enrollment
90
Registered
2013-07-23
Start date
2012-07-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pruritus. Pruritus, unspecified

Interventions

Intervention 1: group1 : 20 mg propofol is injected as bolus ,then 50 mcg/kg/min IV infusion. Intervention 2: group2 :midazolam: 0.03 mg/kg midazolam is injected as bolus dose,then 0.02 mcg/kg/min IV
Prevention
group1 : 20 mg propofol is injected as bolus ,then 50 mcg/kg/min IV infusion.
group2 :midazolam: 0.03 mg/kg midazolam is injected as bolus dose,then 0.02 mcg/kg/min IV infusion
group3: 10 mg propofol and 0.015 mg/kg midazolam are injectes as bolus doses , then 25 mcg/kg/min propofol and 0.01 mcg/kg/min midazolam IV infusion.

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: age:18-65 each sex; elective surgery; major surgery ; ASA class 1 or 2; informed cosent exclusion criteria: spinal anesthesia contraindication; opium addicted patients; emergent surgery; severe COPD; drug allergy to used drug in this study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pruritus. Timepoint: 24 hours after begining the surgery. Method of measurement: questioning the patient about the time, area and the severity of itching.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Jalil Makarem

Tehran University of Medical Sciences

makaremj@yahoo.com+98 21 6658 1576

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026